BlackRock
SLN

BlackRock’s Silence Therapeutics SLN Stock Holding History

BlackRock’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
204,777
+131,624
+180% +$725K ﹤0.01% 4322
2025
Q4 		$445K Buy
73,153
+11,321
+18% +$72.5K ﹤0.01% 4508
2025
Q3 		$321K Sell
61,832
-106,403
-63% -$591K ﹤0.01% 4573
2025
Q2 		$976K Sell
168,235
-12,200
-7% -$52.3K ﹤0.01% 4258
2025
Q1 		$509K Sell
180,435
-31,072
-15% -$152K ﹤0.01% 4395
2024
Q4 		$1.46M Buy
+211,507
New +$2.73M ﹤0.01% 4127

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock's SLN Position: Q1 2026 in Review

BlackRock increased its Silence Therapeutics (SLN) stake by 180% in Q1 2026, buying an estimated $725K and bringing the position to 204,777 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

BlackRock first reported a position in SLN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.46M in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • BlackRock held 204,777 shares of Silence Therapeutics worth $1.08M as of Q1 2026.
  • BlackRock bought 131,624 Silence Therapeutics shares in Q1 2026, an estimated $725K.
  • Silence Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4322 holding.
  • BlackRock first reported a position in Silence Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BlackRock's Silence Therapeutics position peaked at $1.46M in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.